# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number K202007   
B Applicant Lin-Zhi International, Inc.   
C Proprietary and Established Names LZI Oxycodone III Enzyme Immunoassay   
D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>DJG</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 862.3650 -Opiate Test System</td><td rowspan=1 colspan=1>TX - ClinicalToxicology</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: New device   
B Measurand: Oxycodone   
C Type of Test: Qualitative and semi-quantitative enzyme immunoassay

# III Intended Use/Indications for Use:

A Intended Use(s):

See Indications for Use below.

# B Indication(s) for Use:

The LZI Oxycodone III Enzyme Immunoassay is intended for the qualitative and semiquantitative determination of oxycodone in human urine at the cutoff values of $1 0 0 ~ \mathrm { { n g / m L } }$ and $3 0 0 ~ \mathrm { { n g / m L } }$ when calibrated against oxycodone. The assay is designed for prescription use with a number of automated clinical chemistry analyzers.

The semi-quantitative mode is for purposes of (1) enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as GC/MS or LC/MS, or (2) permitting laboratories to establish quality control procedures.

The assay provides only a preliminary analytical result. A more specific alternative chemical method (e.g., gas or liquid chromatography and mass spectrometry) must be used in order to obtain a confirmed analytical result. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary test result is positive.

# C Special Conditions for Use Statement(s):

Rx - For Prescription Use Only

# D Special Instrument Requirements:

Performance characteristics have been validated on the Beckman Coulte $\textsuperscript { \textregistered }$ AU480 clinical analyzer.

# IV Device/System Characteristics:

# A Device Description:

The LZI Oxycodone III Enzyme Immunoassay is a kit comprised of two reagents, an R1 and R2 which are bottled separately but sold together within the kit. The LZI Oxycodone III Enzyme Immunoassay is traceable to a commercially available oxycodone standard.

The R1 solution contains mouse monoclonal anti-oxycodone antibody, glucose-6-phosphate (G6P) nicotinamide adenine dinucleotide (NAD), stabilizers, and sodium azide $( 0 . 0 9 \% )$ as a preservative. The R2 solution contains glucose-6-phosphate dehydrogenase (G6PDH) labeled with oxycodone in buffer with sodium azide $( 0 . 0 9 \% )$ as a preservative.

# B Principle of Operation:

The LZI Oxycodone III Enzyme Immunoassay is a homogeneous enzyme immunoassay with ready-to-use liquid reagents. The assay is based on competition between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for a fixed amount of antibody in the reagent. The drug-labeled G6PDH conjugate is traceable to a commercially available oxycodone standard and referred to as oxycodone-labeled G6PDH conjugate. Enzyme activity decreases upon binding to the antibody, and the drug concentration in the sample is measured in terms of enzyme activity. In the absence of drug in the sample, oxycodone-labeled G6PDH conjugate is bound to antibody, and the enzyme activity is inhibited. If free drug is present in the sample, the antibody would bind to free drug; the unbound oxycodone-labeled G6PDH then exhibits its maximal enzyme activity. Active enzyme converts nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that can be measured spectrophotometrically at $3 4 0 \mathrm { n m }$ .

# V Substantial Equivalence Information:

A Predicate Device Name(s):

LZI Oxycodone Homogeneous Enzyme Immunoassay, LZI Oxycondone Calibrators, LZI Oxycodone Controls

B Predicate 510(k) Number(s):

K120763

C Comparison with Predicate(s):

<table><tr><td rowspan=1 colspan=1>Device &amp; PredicateDevice(s):</td><td rowspan=1 colspan=1>K202007</td><td rowspan=1 colspan=1>K120763</td></tr><tr><td rowspan=1 colspan=1>Device Trade Name</td><td rowspan=1 colspan=1>LZI Oxycodone III EnzymeImmunoassay</td><td rowspan=1 colspan=1>LZI Oxycodone EnzymeImmunoassay</td></tr><tr><td rowspan=1 colspan=1>General DeviceCharacteristicSimilarities</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>IntendedUse/Indications ForUse</td><td rowspan=1 colspan=1>For the qualitative andsemiquantitative determination ofoxycodone in human urine, atcutoff values of 100 ng/mL and300 ng/mL.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Cutoffs</td><td rowspan=1 colspan=1>100 and 300 ng/mL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>General DeviceCharacteristicDifferences</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Calibrator levels</td><td rowspan=1 colspan=1>100 ng/mL Cutoff: 5 Levels: 0,50, 100, 150, and 300 ng/mL300 ng/mL Cutoff: 5 Levels: 0,150, 300, 500, and 800 ng/mL</td><td rowspan=1 colspan=1>0, 50, 100, 300, 500, and800 ng/mL</td></tr></table>

# VI Standards/Guidance Documents Referenced:

None referenced.

VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

1. Precision/Reproducibility:

The precision performance of the assay was evaluated in qualitative and semi-quantitative mode.

All samples were run in replicates of two, with two runs a day for 22 days on one Beckman Coulter $\textsuperscript { \textregistered }$ AU480 automated clinical analyzer for a total of 88 results per concentration.

The oxycodone sample concentrations were prepared by spiking oxycodone into negative urine samples, and all concentrations for the precision studies were confirmed by LC/MS testing. Results are summarized below:

# $\mathbf { 1 0 0 \ n g / m L }$ cutoff semi-quantitative mode:

<table><tr><td rowspan=1 colspan=2>100 ng/mL CutoffResult:</td><td rowspan=1 colspan=2>Within Run (N=22)</td><td rowspan=1 colspan=2>Total Precision (N=88)</td></tr><tr><td rowspan=1 colspan=1>OxycodoneConcentration</td><td rowspan=1 colspan=1>% ofCutoff</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Immunoassay Result</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Immunoassay Result</td></tr><tr><td rowspan=1 colspan=1>0 ng/mL</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative / 0 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative / 0 Positive</td></tr><tr><td rowspan=1 colspan=1>25 ng/mL</td><td rowspan=1 colspan=1>25%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative / 0 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative / 0 Positive</td></tr><tr><td rowspan=1 colspan=1>50 ng/mL</td><td rowspan=1 colspan=1>50%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative / 0 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative / 0 Positive</td></tr><tr><td rowspan=1 colspan=1>75 ng/mL</td><td rowspan=1 colspan=1>75%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative / 0 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative / 0 Positive</td></tr><tr><td rowspan=1 colspan=1>100 ng/mL</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>5 Negative / 17 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>26 Negative / 62 Positive</td></tr><tr><td rowspan=1 colspan=1>125 ng/mL</td><td rowspan=1 colspan=1>125%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0 Negative / 22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>0 Negative / 88 Positive</td></tr><tr><td rowspan=1 colspan=1>150 ng/mL</td><td rowspan=1 colspan=1>150%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0 Negative / 22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>0 Negative / 88 Positive</td></tr><tr><td rowspan=1 colspan=1>175 ng/mL</td><td rowspan=1 colspan=1>175%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0 Negative / 22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>0 Negative / 88 Positive</td></tr><tr><td rowspan=1 colspan=1>200 ng/mL</td><td rowspan=1 colspan=1>200%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0 Negative / 22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>0 Negative / 88 Positive</td></tr></table>

$\mathbf { 1 0 0 \ n g / m L }$ cutoff qualitative mode:   

<table><tr><td rowspan=1 colspan=2>100 ng/mL CutoffResult:</td><td rowspan=1 colspan=2>Within Run (N=22)</td><td rowspan=1 colspan=2>Total Precision (N=88)</td></tr><tr><td rowspan=1 colspan=1>OxycodoneConcentration</td><td rowspan=1 colspan=1>% ofCutoff</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Immunoassay Result</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Immunoassay Result</td></tr><tr><td rowspan=1 colspan=1>0 ng/mL</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative / 0 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative / 0 Positive</td></tr><tr><td rowspan=1 colspan=1>25 ng/mL</td><td rowspan=1 colspan=1>25%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative / 0 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative / 0 Positive</td></tr><tr><td rowspan=1 colspan=1>50 ng/mL</td><td rowspan=1 colspan=1>50%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative / 0 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative / 0 Positive</td></tr><tr><td rowspan=1 colspan=1>75 ng/mL</td><td rowspan=1 colspan=1>75%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative / 0 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative / 0 Positive</td></tr><tr><td rowspan=1 colspan=1>100 ng/mL</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>9 Negative / 13 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>33 Negative / 55 Positive</td></tr><tr><td rowspan=1 colspan=1>125 ng/mL</td><td rowspan=1 colspan=1>125%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0 Negative / 22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>0 Negative / 88 Positive</td></tr><tr><td rowspan=1 colspan=1>150 ng/mL</td><td rowspan=1 colspan=1>150%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0 Negative / 22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>0 Negative / 88 Positive</td></tr><tr><td rowspan=1 colspan=1>175 ng/mL</td><td rowspan=1 colspan=1>175%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0 Negative / 22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>0 Negative / 88 Positive</td></tr><tr><td rowspan=1 colspan=1>200 ng/mL</td><td rowspan=1 colspan=1>200%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0 Negative / 22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>0 Negative / 88 Positive</td></tr></table>

# $\mathbf { 3 0 0 \ n g / m L }$ cutoff semi-quantitative mode:

<table><tr><td rowspan=1 colspan=2>300 ng/mL CutoffResult:</td><td rowspan=1 colspan=2>Within Run (N=22)</td><td rowspan=1 colspan=2>Total Precision (N=88)</td></tr><tr><td rowspan=1 colspan=1>OxycodoneConcentration</td><td rowspan=1 colspan=1>% ofCutoff</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Immunoassay Result</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Immunoassay Result</td></tr><tr><td rowspan=1 colspan=1>0 ng/mL</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative / 0 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative / 0 Positive</td></tr><tr><td rowspan=1 colspan=1>75 ng/mL</td><td rowspan=1 colspan=1>25%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative / 0 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative / 0 Positive</td></tr><tr><td rowspan=1 colspan=1>150 ng/mL</td><td rowspan=1 colspan=1>50%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative / 0 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative / 0 Positive</td></tr><tr><td rowspan=1 colspan=1>225 ng/mL</td><td rowspan=1 colspan=1>75%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative / 0 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative / 0 Positive</td></tr><tr><td rowspan=1 colspan=1>300 ng/mL</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>6 Negative / 16 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>27 Negative / 61 positive</td></tr><tr><td rowspan=1 colspan=1>375 ng/mL</td><td rowspan=1 colspan=1>125%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0 Negative / 22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>0 Negative / 88 Positive</td></tr><tr><td rowspan=1 colspan=1>450 ng/mL</td><td rowspan=1 colspan=1>150%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0 Negative / 22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>0 Negative / 88 Positive</td></tr><tr><td rowspan=1 colspan=1>525 ng/mL</td><td rowspan=1 colspan=1>175%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0 Negative / 22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>0 Negative / 88 Positive</td></tr><tr><td rowspan=1 colspan=1>600 ng/mL</td><td rowspan=1 colspan=1>200%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0 Negative / 22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>0 Negative / 88 Positive</td></tr></table>

$\mathbf { 3 0 0 \ n g / m L }$ cutoff qualitative mode:   

<table><tr><td rowspan=1 colspan=2>300 ng/mL CutoffResult:</td><td rowspan=1 colspan=2>Within Run (N=22)</td><td rowspan=1 colspan=2>Total Precision (N=88)</td></tr><tr><td rowspan=1 colspan=1>OxycodoneConcentration</td><td rowspan=1 colspan=1>% ofCutoff</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Immunoassay Result</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Immunoassay Result</td></tr><tr><td rowspan=1 colspan=1>0 ng/mL</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative / 0 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative / 0 Positive</td></tr><tr><td rowspan=1 colspan=1>75 ng/mL</td><td rowspan=1 colspan=1>25%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative / 0 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative / 0 Positive</td></tr><tr><td rowspan=1 colspan=1>150 ng/mL</td><td rowspan=1 colspan=1>50%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative / 0 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative / 0 Positive</td></tr><tr><td rowspan=1 colspan=1>225 ng/mL</td><td rowspan=1 colspan=1>75%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative / 0 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative / 0 Positive</td></tr><tr><td rowspan=1 colspan=1>300 ng/mL</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>10 Negative / 12 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>40 Negative / 48 Positive</td></tr><tr><td rowspan=1 colspan=1>375 ng/mL</td><td rowspan=1 colspan=1>125%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0 Negative / 22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>0 Negative / 88 Positive</td></tr><tr><td rowspan=1 colspan=1>450 ng/mL</td><td rowspan=1 colspan=1>150%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0 Negative / 22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>0 Negative / 88 Positive</td></tr><tr><td rowspan=1 colspan=1>525 ng/mL</td><td rowspan=1 colspan=1>175%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0 Negative / 22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>0 Negative / 88 Positive</td></tr><tr><td rowspan=1 colspan=1>600 ng/mL</td><td rowspan=1 colspan=1>200%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0 Negative / 22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>0 Negative / 88 Positive</td></tr></table>

2. Linearity:

Linearity and recovery were evaluated in the semi-quantitative mode by analyzing serial dilutions of a sample with an oxycodone concentration of $3 0 0 ~ \mathrm { { n g / m L } }$ (for the $1 0 0 ~ \mathrm { { n g / m L } }$ cutoff) and an $8 0 0 ~ \mathrm { { n g / m L } }$ concentration sample (for the $3 0 0 ~ \mathrm { { n g / m L } }$ cutoff). Results are summarized below:

$1 0 0 ~ \mathrm { { n g / m L } }$ cutoff   

<table><tr><td rowspan=1 colspan=1>Target Concentration(ng/mL)</td><td rowspan=1 colspan=1>Mean Concentration(ng/mL)</td><td rowspan=1 colspan=1>Mean% Recovery</td></tr><tr><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>302.1</td><td rowspan=1 colspan=1>100.7 %</td></tr><tr><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>282.7</td><td rowspan=1 colspan=1>104.7 %</td></tr><tr><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>260.4</td><td rowspan=1 colspan=1>108.5 %</td></tr><tr><td rowspan=1 colspan=1>210</td><td rowspan=1 colspan=1>231.0</td><td rowspan=1 colspan=1>110.0 %</td></tr><tr><td rowspan=1 colspan=1>180</td><td rowspan=1 colspan=1>197.0</td><td rowspan=1 colspan=1>109.5 %</td></tr><tr><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>153.6</td><td rowspan=1 colspan=1>102.4 %</td></tr><tr><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>121.4</td><td rowspan=1 colspan=1>101.2 %</td></tr><tr><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>88.8</td><td rowspan=1 colspan=1>98.6 %</td></tr><tr><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>56.9</td><td rowspan=1 colspan=1>94.8 %</td></tr><tr><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>27.1</td><td rowspan=1 colspan=1>90.3 %</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>N/A</td></tr></table>

$3 0 0 ~ \mathrm { { n g / m L } }$ cutoff   

<table><tr><td rowspan=1 colspan=1>Target Concentration(ng/mL)</td><td rowspan=1 colspan=1>Mean Concentration(ng/mL)</td><td rowspan=1 colspan=1>Mean% Recovery</td></tr><tr><td rowspan=1 colspan=1>800</td><td rowspan=1 colspan=1>843.5</td><td rowspan=1 colspan=1>105.4 %</td></tr><tr><td rowspan=1 colspan=1>720</td><td rowspan=1 colspan=1>784.2</td><td rowspan=1 colspan=1>108.9 %</td></tr><tr><td rowspan=1 colspan=1>640</td><td rowspan=1 colspan=1>712.8</td><td rowspan=1 colspan=1>111.4 %</td></tr><tr><td rowspan=1 colspan=1>560</td><td rowspan=1 colspan=1>624.3</td><td rowspan=1 colspan=1>111.5 %</td></tr><tr><td rowspan=1 colspan=1>480</td><td rowspan=1 colspan=1>514.2</td><td rowspan=1 colspan=1>107.1 %</td></tr><tr><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>436.8</td><td rowspan=1 colspan=1>109.2 %</td></tr><tr><td rowspan=1 colspan=1>320</td><td rowspan=1 colspan=1>345.0</td><td rowspan=1 colspan=1>107.8 %</td></tr><tr><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>250.8</td><td rowspan=1 colspan=1>104.5 %</td></tr><tr><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>173.9</td><td rowspan=1 colspan=1>108.7 %</td></tr><tr><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>89.0</td><td rowspan=1 colspan=1>111.2 %</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>N/A</td></tr></table>

# 3. Analytical Specificity/Interference:

Cross-reactivity

The cross-reactivity of structurally related compounds was tested by spiking each potential cross-reactant into pooled negative human urine and then evaluating the sample with the candidate assay. Results are summarized below using the $1 0 0 ~ \mathrm { { n g / m L } }$ cutoff. Results obtained using the $3 0 0 ~ \mathrm { { n g / m L } }$ cutoff were nearly identical.

<table><tr><td colspan="1" rowspan="1">Potential Cross-ReactingCompound</td><td colspan="1" rowspan="1">TestConcentration(ng/mL)</td><td colspan="1" rowspan="1">% Cross-reactivity</td></tr><tr><td colspan="1" rowspan="1">Oxycodone</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">100.00 %</td></tr><tr><td colspan="1" rowspan="1">Oxymorphone</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">100.00 %</td></tr><tr><td colspan="1" rowspan="1">Noroxycodone</td><td colspan="1" rowspan="1">25,000</td><td colspan="1" rowspan="1">0.40 %</td></tr><tr><td colspan="1" rowspan="1">Noroxymorphone</td><td colspan="1" rowspan="1">60,000</td><td colspan="1" rowspan="1">0.17 %</td></tr><tr><td colspan="1" rowspan="1">6-Acetylmorphine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Buprenorphine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Codeine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Codeine-6β-D-Glucuronide</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Dextromethorphan</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Dihydrocodeine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Hydrocodone</td><td colspan="1" rowspan="1">25,000</td><td colspan="1" rowspan="1">0.40 %</td></tr><tr><td colspan="1" rowspan="1">Hydromorphone</td><td colspan="1" rowspan="1">25,000</td><td colspan="1" rowspan="1">0.40 %</td></tr><tr><td colspan="1" rowspan="1">Levorphanol</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Morphine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Morphine-3β-D-Glucuronide</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Morphine-6β-D-Glucuronide</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Naloxone</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Naloxone-3β-D-Glucuronide</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Norbuprenorphine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Norcodeine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Norhydrocodone</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Oxymorphone-3β-D-Glucuronide</td><td colspan="1" rowspan="1">230</td><td colspan="1" rowspan="1">43.48 %</td></tr></table>

Interference Testing - Drugs

Potential interference from structurally unrelated compounds was evaluated by spiking a high concentration (as noted in the table below) of the potential interferent into two sample aliquots with oxycodone concentrations at $- 2 5 \%$ and $+ 2 5 \%$ of the cutoff concentration. Samples were then evaluated with the candidate assay and the results are summarized below.

There were no deviations from the expected positive or negative results.

<table><tr><td colspan="1" rowspan="2">Compound</td><td colspan="1" rowspan="2">TestConcentration(ng/mL)</td><td colspan="1" rowspan="1">-25 %OxycodoneCutoff (75ng/mL)</td><td colspan="1" rowspan="1">+25 %OxycodoneCutoff (125ng/mL)</td></tr><tr><td colspan="1" rowspan="1">Result</td><td colspan="1" rowspan="1">Result</td></tr><tr><td colspan="1" rowspan="1">Amlodipine Besylate</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Amoxicillin</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">d-Amphetamine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Atorvastatin</td><td colspan="1" rowspan="1">20,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Benzoylecgonine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Bupropion</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Carbamazepine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Cetirizine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Chlorpheniramine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Chlorpromazine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Clomipramine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Desipramine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Diphenhydramine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Duloxetine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Fentanyl</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Fluoxetine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Fluphenazine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Gabapentin</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Imipramine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Lisinopril</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Losartan</td><td colspan="1" rowspan="1">10,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Loratadine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">MDA (3,4-methylenedioxyamphetamine)</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">MDEA</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">MDMA (3,4-methylenedioxymethamphetamine)</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Meperidine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Metformin</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Metoprolol</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Methadone</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">d-Methamphetamine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Nicotine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Nortriptyline</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Omeprazole</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Oxazepam</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Phenobarbital</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">(1S,2S)-(+)Pseudoephedrine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Quetiapine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Ranitidine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Salbutamol (Albuterol)</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Sertraline</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">THC-COOH(11-Nor-Delta-9-THC-9-carboxylic acid)</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">l-Thyroxine</td><td colspan="1" rowspan="1">10,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Tramadol</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Zolpidem</td><td colspan="1" rowspan="1">10,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr></table>

Potential interference from endogenous compounds and urine preservatives was also evaluated in a separate study. Results indicated that there is interference from boric acid at $1 0 0 0 \mathrm { m g / d L }$ . No other compounds showed interference concentrations at the concentrations tested. Results are summarized below:

<table><tr><td rowspan=2 colspan=1>Potential InterferingEndogenous Substance</td><td rowspan=2 colspan=1>Concentrationof Compound(mg/dL)</td><td rowspan=1 colspan=1>-25 % OxycodoneCutoff (75ng/mL)</td><td rowspan=1 colspan=1>+25 % OxycodoneCutoff (125ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>Acetone</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>1500</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Calcium Chloride (CaC12)</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Citric Acid (pH 3)</td><td rowspan=1 colspan=1>800</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Ethanol</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Galactose</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>γ-Globulin</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Glucose</td><td rowspan=1 colspan=1>3000</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>β-hydroxybutyric Acid</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Human Serum Albumin</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Oxalic Acid</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Potassium Chloride</td><td rowspan=1 colspan=1>6000</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Riboflavin</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Urea</td><td rowspan=1 colspan=1>6000</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Uric Acid</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Sodium Azide</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Sodium Chloride</td><td rowspan=1 colspan=1>6000</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Sodium Fluoride</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Sodium Phosphate</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr></table>

Boric acid at $1 0 0 0 \mathrm { m g / d L }$ was found to cause false negative results at $+ 2 5$ and $+ 5 0 \%$ of the cutoff. The following limitation is included in the device labeling: Boric Acid at $1 \% w \%$ may cause false negative results. Boric Acid is not recommended as a preservative for urine.

Effect of pH

The sponsor evaluated the effect of $\mathsf { p H }$ on the results by preparing aliquots with oxycodone concentrations at $- 2 5 \%$ and $+ 2 5 \%$ of the cutoff and adjusting the pH from 3 to 11 in increments of one $\mathsf { p H }$ unit. There were no deviations from the expected positive or negative results.

Effect of specific gravity

The sponsor evaluated the effect of specific gravity on the results by preparing aliquots with oxycodone concentrations at $- 2 5 \%$ and $+ 2 5 \%$ of the cutoff and adjusting the specific gravity from 1.000 to 1.030. There were no deviations from the expected positive or negative results.

4. Assay Reportable Range: Not applicable.

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

The LZI Oxycodone III Enzyme Immunoassay is traceable to a commercially available oxycodone standard.

6. Detection Limit: Not applicable.

7. Assay Cut-Off:

The performance of the assay around the claimed cutoffs is presented in sections VII.A.1 and VII.A.2 above.

# B Comparison Studies:

# 1. Method Comparison with Predicate Device:

For the 100 ng/mL cutoff, the sponsor conducted a method comparison study using 82 unaltered clinical urine samples comparing results on the candidate device to those using a validated LC-MS/MS method. Since the assay demonstrated $100 \%$ cross-reactivity with oxymorphone, samples were binned according to the sum of the oxycodone and oxymorphone concentrations, which ranged from 0 to $4 0 0 . 0 \mathrm { n g / m L }$ . The results were identical between the qualitative and semi-quantitative modes and are summarized in the tables below:

<table><tr><td rowspan=1 colspan=1>Candidatedeviceresults</td><td rowspan=1 colspan=1>&lt; 50 % of thecutoffconcentrationby LC/MSanalysis</td><td rowspan=1 colspan=1>Near CutoffNegative(Between 50%below the cutoffand the cutoffconcentration byLC/MS analysis)</td><td rowspan=1 colspan=1>Near CutoffPositive (Betweenthe cutoff and 50% above theCutoff concentrationby LC/MS analysis</td><td rowspan=1 colspan=1>High Positive(Greater than 50% above thecutoffconcentration byLC/MS analysis)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2*</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>4**</td><td rowspan=1 colspan=1>0</td></tr></table>

\*concentrations of the discordant samples were 89.9 and $9 1 . 0 \mathrm { n g / m L }$ .   
\*\*concentrations of the discordant samples were 102.7, 107.0, 131.1, and $1 3 8 . 7 \mathrm { n g / m L }$ .

For the 300 ng/mL cutoff, the sponsor conducted a method comparison study using 90 unaltered clinical urine samples comparing results on the candidate device to those using a validated LC-MS/MS method. Since the assay demonstrated $100 \%$ cross-reactivity with oxymorphone, samples were binned according to the sum of the oxycodone and oxymorphone concentrations, which ranged from 0 to $1 3 0 2 . 5 ~ \mathrm { n g / m L }$ . There were slight differences between the qualitative and semi-quantitative modes and results for both modes are summarized in the tables below:

Semi-quantitative mode   

<table><tr><td rowspan=1 colspan=1>Candidatedeviceresults</td><td rowspan=1 colspan=1>&lt; 50 % of thecutoffconcentrationby LC/MSanalysis</td><td rowspan=1 colspan=1>Near CutoffNegative(Between 50%below the cutoffand the cutoffconcentration byLC/MS analysis)</td><td rowspan=1 colspan=1>Near CutoffPositive (Betweenthe cutoff and 50% above theCutoff concentrationby LC/MS analysis</td><td rowspan=1 colspan=1>High Positive(Greater than 50% above thecutoffconcentration byLC/MS analysis)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2*</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>33</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>1**</td><td rowspan=1 colspan=1>0</td></tr></table>

\*concentrations of the discordant samples were 249.7 and $2 5 6 . 5 \mathrm { n g / m L }$ \*\*concentration of the discordant sample was $4 1 4 . 0 \mathrm { n g / m L }$ .

Qualitative mode   

<table><tr><td rowspan=1 colspan=1>Candidatedeviceresults</td><td rowspan=1 colspan=1>&lt; 50 % of thecutoffconcentrationby LC/MSanalysis</td><td rowspan=1 colspan=1>Near CutoffNegative(Between 50%below the cutoffand the cutoffconcentration byLC/MS analysis)</td><td rowspan=1 colspan=1>Near CutoffPositive (Betweenthe cutoff and 50% above theCutoff concentrationby LC/MS analysis</td><td rowspan=1 colspan=1>High Positive(Greater than 50% above thecutoffconcentration byLC/MS analysis)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2*</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>33</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>2**</td><td rowspan=1 colspan=1>0</td></tr></table>

\*concentrations of the discordant samples were 249.7 and $2 5 6 . 5 \mathrm { n g / m L }$ . \*\*concentrations of the discordant samples were 389.3 and $4 1 4 . 0 \mathrm { n g / m L }$

2. Matrix Comparison: Not applicable. The assay is for use with urine samples only.

# C Clinical Studies:

1. Clinical Sensitivity: Not applicable.

2. Clinical Specificity: Not applicable.

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not applicable.

D Clinical Cut-Off: Not applicable.   
E Expected Values/Reference Range: Not applicable.

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.